Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma

Inter-individual differences in toxic symptoms and pharmacokinetics of high-dose methotrexate (MTX) treatment may be caused by genetic variants in the MTX pathway. Correlations between polymorphisms and pharmacokinetic parameters and the occurrence of hepato- and myelotoxicity were studied. Single n...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegyi, Marta, Arany, Adam, Semsei, Agnes F., Csordas, Katalin, Eipel, Oliver, Gezsi, Andras, Kutszegi, Nora, Csoka, Monika, Muller, Judit, Erdelyi, Daniel J., Antal, Peter, Szalai, Csaba, Kovacs, Gabor T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354739/
https://www.ncbi.nlm.nih.gov/pubmed/27566582
http://dx.doi.org/10.18632/oncotarget.11543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354739/
https://www.ncbi.nlm.nih.gov/pubmed/27566582
http://dx.doi.org/10.18632/oncotarget.11543

Ejemplares similares